WO1996036339A3 - Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme - Google Patents

Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme Download PDF

Info

Publication number
WO1996036339A3
WO1996036339A3 PCT/US1996/006078 US9606078W WO9636339A3 WO 1996036339 A3 WO1996036339 A3 WO 1996036339A3 US 9606078 W US9606078 W US 9606078W WO 9636339 A3 WO9636339 A3 WO 9636339A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydrotestosterone
sexual dysfunction
compounds
male sexual
treating male
Prior art date
Application number
PCT/US1996/006078
Other languages
English (en)
Other versions
WO1996036339A2 (fr
Inventor
Christo S Mantzoros
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Priority to EP96913887A priority Critical patent/EP0827405A2/fr
Priority to AU56714/96A priority patent/AU5671496A/en
Publication of WO1996036339A2 publication Critical patent/WO1996036339A2/fr
Publication of WO1996036339A3 publication Critical patent/WO1996036339A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention décrit une méthode de traitement d'une dysfonction sexuelle chez un patient, consistant à élever les taux de dihydrotestostérone (DHT) chez un patient pour traiter efficacement ladite dysfonction sexuelle. Les méthodes de l'invention peuvent être utilisées dans le cadre d'un traitement prophylactique et/ou thérapeutique des dysfonctions sexuelles.
PCT/US1996/006078 1995-05-15 1996-05-01 Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme WO1996036339A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96913887A EP0827405A2 (fr) 1995-05-15 1996-05-01 Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme
AU56714/96A AU5671496A (en) 1995-05-15 1996-05-01 Use of dihydrotestosterone compounds for treating male sexual dysfunction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44072695A 1995-05-15 1995-05-15
US08/440,726 1995-05-15
US48747195A 1995-06-07 1995-06-07
US08/487,471 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996036339A2 WO1996036339A2 (fr) 1996-11-21
WO1996036339A3 true WO1996036339A3 (fr) 1997-02-13

Family

ID=27032530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006078 WO1996036339A2 (fr) 1995-05-15 1996-05-01 Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme

Country Status (4)

Country Link
EP (1) EP0827405A2 (fr)
AU (1) AU5671496A (fr)
CA (1) CA2219082A1 (fr)
WO (1) WO1996036339A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
WO2005107810A2 (fr) 2004-05-11 2005-11-17 Emotional Brain B.V. Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
EP1790343A1 (fr) 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.D. MOORADIAN ET AL.: "Biological actions of androgens.", ENDOCR. REV., vol. 8, no. 1, 1987, pages 1 - 28, XP000612870 *
G.R. CUNNINGHAM ET AL.: "Testosterone replacement therapy and sleep-related erections in hypogonadal men.", J. CLIN. ENDOCRINOL. METAB., vol. 70, no. 3, 1990, pages 792 - 797, XP000612829 *
J.M. DAVIDSON ET AL.: "Hormonal replacement and sexuality in men.", CLIN. ENDOCRINOL. METAB., vol. 11, no. 3, 1982, pages 599 - 623, XP000612869 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Also Published As

Publication number Publication date
AU5671496A (en) 1996-11-29
EP0827405A2 (fr) 1998-03-11
CA2219082A1 (fr) 1996-11-21
WO1996036339A2 (fr) 1996-11-21

Similar Documents

Publication Publication Date Title
WO2000059487A3 (fr) Utilisation de flupirtine pour le traitement de la fibromyalgie et d'affections associees a la fibromyalgie
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
AU4696499A (en) Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
EP1143987A4 (fr) Composition naturelle et methode destinees au traitement de dysfonctions sexuelles
ZA966844B (en) Engine exhaust treatment apparatus and method of use.
GB2382993B (en) Apparatus and method for treating female urinary incontinence
HK1057740A1 (en) Method for treatment of water and wastewater
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
AP2003002875A0 (en) Apparatus and method for treatment of water.
EP1136141A4 (fr) Procede et appareil de traitement et procede de traitement des sols
AU5729098A (en) Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
WO2002019213A3 (fr) Procede de traitement de la migraine
CA2262268A1 (fr) Methode pour traiter l'impuissance causee par des lesions a la moelle epiniere
CA2247063A1 (fr) Traitement contre l'oedeme maculaire
AU3894600A (en) Method of treating sexual dysfunction
WO1996036339A3 (fr) Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme
EP0358386A3 (fr) Méthode pour le traitement de la laine
EP0817645A4 (fr) Methode de traitement de l'hypertrophie prostatique benigne
AUPP010397A0 (en) Method and composition for treatment of sexual dysfunction
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels
NZ324615A (en) Method for treating autism using olanzapine
AU6970101A (en) Method for treatment and prevention of mastitis
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
HK1059391A1 (en) Use of quetiapine for the treatment of cocaine dependence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2219082

Country of ref document: CA

Ref country code: CA

Ref document number: 2219082

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996913887

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996913887

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996913887

Country of ref document: EP